Bit by bit, the IPO market is picking up steam. And, the latest deal hit the markets today: Medidata (NASDAQ: MDSO).

So far, the shares are up 19% $16.70 (the IPO priced at $14, which was above its $11-$13 price range).

Founded about ten years ago, Medidata develops web-based software for clinical trials management. Obviously, it's a big market opportunity.

Keep in mind that a drug costs more than $1 billion to develop. Oh, and the process can easily go beyond a decade. In other words, it's important to streamline the process.

The green shoots are getting harder to keep pumping up as it seems that Wall Street is starting to demand some visible improvements rather than the continued notion of just "less-bad" data. The weak manufacturing data today makes it look like the factories are taking a European summer vacation.

The good news is that producer inflation has not yet started working itself into the system, based on PPI data. The housing starts looked unbelievably better than estimates, but that was due to apartment projects rather than single-family activity.

Here were today's unofficial closing bell levels:

DJIA
S&P500
NASDAQ

Top Analyst Calls

Today was a negative market from the start of trading, and the economic data just confirmed the selling, as hunting for green shoots looked more like hunting for four-leaf clovers. It seems that those analysts and economists saying that the market has risen too far and too fast are getting some more ears than in recent weeks.

The housing data showed a dip after two months of rising data, and the New York Empire Manufacturing data came in weaker than expected. Even the Iran turmoil after the election failed to rally oil. Here were today's unofficial closing bell levels:

Dow 8,613.04 -186.22 (-2.12%)
S&P 500 923.81 -22.40 (-2.37%)
Nasdaq 1,816.38 -42.42 (-2.28%)

Top 10 Analyst Calls

eBay (NASDAQ: EBAY) closed at $14.29. EBAY is scheduled to report Q1 EPS after the market close today. EBAY May option implied volatility of 56 is below its 26-week average of 61, according to Track Data, suggesting decreasing price movement.

Amgen (NASDAQ: AMGN) closed at $46.09. AMGN Q1 EPS are expected on April 24. AMGN's Denosumab for treatment/prevention of postmenopausal osteoporosis and for bone loss in prostrate or breast cancer patients on hormone ablation therapy has a FDA action date of October 19. AMGN May and July option implied volatility of 44 is near its 26-week average according to Track Data, suggesting non-directional price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

When a $7 a share biotechnology company like Dendreon Corp. (NASDAQ: DNDN) rockets 200% to over $20 a share in one day, like it did yesterday after reporting successful Phase 3 trials of its prostate cancer drug, investors get interested in any biotech stock under $10.

But before investing in these speculative companies, you should have a clear understanding of how this niche operates. Marketing plays an important role in order for the companies to raise capital, therefore if you are interested in betting on a company's future, you should consider the risk factors and odds of success.

TheStreet.com's Jim Cramer says if you need money for anything important in the near future, get it out of the stock market.

Fall back. Fall back to basic principles. What do people have to do whether they want to do it or not? What do governments have to pay for whether they want something or not? What must be used whether you like it or not?

That's where we are right now in the helter-skelter pell-mell race to take all stocks to single digits as the notion of a worldwide global depression sinks in.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Altria Group Inc. (NYSE: MO) Q4 profit rose on higher prices, and its forecast matched expectations.
• Amgen Inc. (NASDAQ: AMGN) Q4 earnings grew on cost cutting but revenue remained flat.
• Black & Decker Corp. (NYSE: BDK) shares tanked after the dismal Q4 report, and it announced job cuts.
• Carpenter Technology Corp. (NYSE: CRS) Q2 numbers resulted in a downgrade from one analyst.
• ConocoPhillips (NYSE: COP) reported a Q4 loss due to writedowns from recent acquisitions.
• DuPont (NYSE: DD) swung to a bigger-than-expected Q4 loss and its revenue fell as well.
• Eli Lilly & Co. (NYSE: LLY) swung to a Q4 loss on acquisition costs but reaffirmed its guidance.

DuPont (NYSE: DD) reported Tuesday morning, saying it swung to a fourth-quarter loss. DuPont reported a loss of $629 million, or 70 cents per share, but excluding a restructuring charge the loss is 28 cents per share. Revenue fell 16% to $6.07 billion. Results were below analyst estimates of a loss of 24 cents per share on revenue of $6.17 billion.

Verizon Communications (NYSE: VZ) also reported Tuesday morning, saying it earned $1.24 billion, or 43 cents a share, in the fourth quarter. On an adjusted basis, Verizon earned 61 cents a share compared to 62 cents a share a year ago. Sales were $24.6 billion. Verizon missed estimates only slightly and shares gained 1.6% in premarket trading.

Yahoo (NASDAQ: YHOO) is reporting after the close today and analysts expect earnings of 13 cents a share for the period, on $1.4 billion in net revenue, according to FactSet Research. Shares indicated higher in premarket trading.

Here's a quick look at some of Monday's earnings results:

Netflix Inc.'s (NASDAQ: NFLX) fourth-quarter earnings jumped 45% percent to nearly $23 million, or 38 cents per share, which surpassed analysts' estimates. Revenue in the period rose 19% to $360 million. The company ended 2008 with 9.4 million subscribers, a gain of 718,000 customers from the end of September. Shares fell $0.29, less than 1% Monday.

Amgen Inc.'s (NASDAQ: AMGN) fourth-quarter profit grew 15% percent to $961 million, or 91 cents per share, mostly due to lower expenses. Revenue was $3.75 billion about the same as last year. Results included $60 million in restructuring costs a year ago. Shares rose $1.22, or 2.3%, but fell in after-hours trading.

Pfizer Inc. (NYSE: PFE) announced a deal to acquire rival Wyeth (NYSE: WYE) for $68 billion, or $50.19 a share, a 15% premium to Friday's close of $43.74. This cash-and-stock deal is the largest in the drug sector since 2000 and many see it as a precursor to a flourishing M&A season as the credit markets are slowly starting to improve. Pfizer also reported a 90% profit drop for the fourth quarter due to charges. PFE shares declined 3.4% in premarket trading, while WYE shares gained nearly 5%.

Barclays (NYSE: BCS) shares surged in London Monday after the firm reassured investors in a letter to shareholders it didn't need more capital. But France's BNP Paribas said it would take more cash from the government following a 1.4 billion euro ($1.8 billion) loss in the latest quarter. Finally, ING (NYSE: ING), the Dutch financial services firm, also received government aid as it is expected to announce it had a net loss of 3.3 billion euros in the fourth quarter, that it would cut 7,000 jobs, and that its CEO would step down. BCS shares gained over 44% in premarket trading and ING's gained over 19%.

Caterpillar (NYSE: CAT) and McDonald's (NYSE: MCD) are two Dow components set to report earnings this morning. CAT said its fourth-quarter profit fell to $661 million, or $1.08 a share, from $975 million, or $1.50 a share, in the year-ago quarter. Revenue rose 6% to $12.9 billion. For 2009, Caterpillar gave a a much lower guidance than analysts had expected, $2.50 vs. $4.35 EPS. CAT also said it would slash 20,000 jobs. CAT shares fell over 11% in premarket trading.
Meanwhile, MCD delivered what at first glance seems to be better-than-expected earnings of 87 cents vs. 84 cents. It even plans to invest $2.1 billion of capital to open about 1,000 new McDonald's restaurants.

American Express (NYSE: AXP) is the third Dow component tor report quarterly results after the close of trading today and is expected to report fourth-quarter earnings of 20 cents a share.

It was a quiet week, but here are highlights from this past week's earnings coverage from BloggingStocks:

• Amgen Inc. (NASDAQ: AMGN) earnings growth prospects for 2009 make the stock worth a look.
• Big Lots Inc. (NYSE: BIG) offered no 2009 guidance but may benefit from bankruptcies of other retailers.
• Cal-Maine Foods Inc. (NASDAQ: CALM) Q2 earnings fell more than expected but revenue rose.
• Chevron Corp. (NYSE: CVX) said it will soon post preliminary Q4 results in the face of falling oil prices.
• Piedmont Natural Gas Co. Inc. (NYSE: PNY) reported a widened Q4 loss while revenue improved.
• Take-Two Interactive Software Inc. (NASDAQ: TTWO) earnings prospects may make the stock a bargain.

Also, a survey indicated that U.S. corporate profits in the fourth quarter probably fell for the sixth straight quarter. Interest cuts haven't helped bank earnings, will the Fed buying mortgage-backed securities do better? And, are food stocks still a defensive play?

Upcoming earnings releases include Bed Bath & Beyond (NASDAQ: BBBY), Constellation Brands (NYSE: STZ), Family Dollar (NYSE: FDO), and Monsanto (NYSE: MON).

Visit AOL Money & Finance for more earnings coverage.

The first trading session of the 2009 may have brought some optimism with it as markets rallied, but it's difficult to imagine all our troubles over after a year that set one bad and worse record after another. Stocks mirrored the global economic slowdown brought on by the housing market and the financial markets crises.

Still, there are many who still seek to invest in hope that one day they could get nice returns on their investments. While the recent volatility in the stock market benefited some shrewd day traders, most investors know to stick to a long-term, stable investment plan.

To help achieve some of these long-term return, BloggingStocks contributors continued to suggest some companies to invest in, as well as some to avoid:

Activision Blizzard (NASDAQ: ATVI) -- despite having his confidence in the stock shaken somewhat lately as sales may have been softer than expected, Steven Mallas is still bullish on the stock and feels it is attractive at these levels. Take-Two Interactive (NASDAQ: TTWO), however, "seems a little scary to be buying in now," he says.

In the News:
Family Dollar Stores is King
Stock losses this year were broad based and dramatic. But there were a few that escaped the carnage. 25 stocks in the S&P 500 actually finished higher in the worst stock market in 77 years. Topping the list is Family Dollar which rose 38.5%. Other top stocks included Amgen, H&R Block, Wal-Mart, Hasbro, General Mills, McDonald's and Darden Restaurants.
http://money.cnn.com/2008/12/31/markets/SP500_year_end/index.htm?postversion=2008123117

2009 Dogs of the Dow
This popular investment strategy defines a portfolio by equal dollar value investments into the 10 highest yielding Dow stocks at the end of a year. This year's list includes Bank of America, GE, Pfizer, duPont, Alcoa, AT&T, Verizon, Merck, JP Morgan Chase and Kraft Foods.
http://www.cnbc.com/id/28448355

There were a few stocks in 2008 that exhibited great performance despite horrible market conditions. And these gems of 2008 may provide investors with a safe haven of sorts for 2009.

In fact, we are already hearing analysis of the year to come suggesting that biotechnology stocks will be the place to be for positive returns in the new year.

One such name to consider is Amgen (NASDAQ: AMGN).

Founded in 1980, AMGN is one of the largest biotechnology companies in the market. It has a stable of proven drugs that provides significant profits, and a pipeline of opportunities that should provide reasonable growth in the future.

Shares of AMGN have gained approximately 20% during the last year as investors recognized the value of current profits combined with future growth. Interestingly, the company really gained traction during the second half of the year as the rest of the market was imploding.

Even with the gains, AMGN is a compelling investment story.

Shares trade for 15 times trailing earnings and only 12 times forward earnings. That means you can buy shares for a price-to-earnings ratio that is lower than its growth rate.

One reason for the optimism in the stock in 2008 was the progress made on its osteoporosis drug, Denosumab. Analysts are expecting the drug to be a blockbuster.

Denosumab has done well in trials, and AMGN recently applied for FDA approval to bring the drug to market. Given the expected 10-month FDA review and processing period, AMGN is only a year or so away from the sales benefits of this new drug.

Voting continues in our Best & Worst in Money 2008 feature, and it looks like early favorites include falling gasoline prices, Wal-Mart, Joe the Plumber, and former New York Governor Eliot Spitzer. Did they get your vote?

Close races include the Breakout Person of the Year, in which vice presidential contender Sarah Palin and Olympic gold medal winner Michael Phelps duke it out for first place, while poor Neel Kashkari, who is in charge of the U.S. Treasury's financial relief funds, is in last place with only about 6% of the vote.

The Most Disturbing Consumer Trend is another close race, with plunging retirement accounts and falling home values virtually a tie. It's also a very close race between Wall Street and Kmart for Most in Need of a Makeover. Not much interest in making over Starbucks (NASDAQ: SBUX), however, as it has only about 4% of the vote in that category.

Lower fuel prices are clearly the most popular Silver Lining to the Recession with about 62% of the vote so far. Joe the Plumber, with 57% of the vote, has a clear lead over distant second place Rev. Jeremiah Wright as the Most Notable 15 Minutes of Fame. And disgraced New York Governor Eliot Spitzer leads the Biggest Fall from Grace category with about 56% of the vote.